Abstract Targeted molecular therapies inhibit proliferation and survival of cancer cells but may also aVect immune cells. We have evaluated the eVects of Sirolimus and Sorafenib on proliferation and survival of lymphoid cell subsets. Both drugs were cytotoxic to CD4 + CD25 high T cells, and were growth inhibitory for CD4 + and CD8 +
T cells. Cytotoxicity depended on CD3/CD28 stimulation and was detectable within 12 h, with 80-90% of CD4 + CD25
high cells killed by 72 h. Cell death was due to apoptosis, based on Annexin V and 7AAD staining. Addition of IL-2 prevented the apoptotic response to Sirolimus, potentially accounting for reports that Sirolimus can enhance proliferation of CD4 + CD25 high cells. These results predict that Sirolimus or Sorafenib would reduce CD4 + CD25
high cells if administered prior to antigenic stimulation in an immunotherapy protocol. However, administration of IL-2 protects CD4
Introduction
Novel targeted therapies for cancer include immune therapy and small molecule targeted therapies. Immune therapy may include cancer vaccines or adoptive T cell therapy. Targeted therapies inhibit cell signaling pathways critical for cancer cell growth, division, and metastasis. There is rationale for considering combinations of these approaches. Inhibitors of cell signaling pathways for growth, proliferation, or survival might enhance immunotherapy by making tumors more susceptible to killing by cytotoxic CD8 + T cells. However, inhibitors of cell signaling might interfere with the immune response because many of the pathways critical for tumor cell growth and division are also critical to T-cell activation and expansion.
We performed studies to assess the eVects on T-cell proliferation of Sirolimus and Sorafenib, two signal transduction inhibitors currently in clinical practice and development. Sirolimus (Rapamycin) is an FDA-approved agent, used since the late 1990s as immunosuppressive therapy to prevent rejection of transplanted organ allografts [4, 17] . Another inhibitor of mTOR signaling, temsirolimus (CCI-779, Wyeth Pharmaceuticals), is a derivative of Sirolimus and is being evaluated in clinical trials as a cancer therapeutic. Sirolimus binds to a cytoplasmic receptor, FKBP12, and the drug-protein complex inhibits the function of mTOR kinase, an important cellular regulator of translation and transcription [3] . Sorafenib (BAY43-9006) was approved by the FDA in December 2005 for treatment of renal cell cancer [7] and in November 2007 for unresectable hepatocellular carcinoma. It was developed as a B-Raf kinase inhibitor in part because B-Raf has been identiWed as mutated and over-expressed in multiple cancers, especially melanoma. Sorafenib also inhibits VEGF-R kinases (1/2/3) and other tyrosine kinases, all of which may contribute to its therapeutic actions [1, 27] . The eVects of Sorafenib on lymphocyte subsets have not been explored. In prior work, we have found that nanomolar doses of Sirolimus and Sorafenib can inhibit human melanoma cell proliferation, and we have been interested in exploring the eVects of these doses of those agents on human lymphocyte proliferation [14] .
The T cell population of CD4 + CD25 high has attracted particular attention because of regulatory activity of tumor suppressor cells [8, 12] . One desirable scenario would be to inhibit this population of cells selectively, without eliminating the remaining CD4 + or CD8 + T cells to improve the eYcacy of immunization therapy. One would expect that an mTOR inhibitor such as Sirolimus would suppress the proliferation of T cells, however, Sirolimus has been reported to expand the CD4 + CD25 high T cells selectively in culture [2, 23] . Here we examine the eVects of Sirolimus and Sorafenib on the proliferation and survival of CD4 +
CD25
high T cells compared to CD4 + and CD8 + T cells.
Materials and methods

Cell separation
Peripheral blood mononuclear cells (PBMC) were isolated from 20 healthy human volunteers, using the following sources: Ficoll gradient centrifugation of whole blood, anonymous donor buVy coats from Virginia Blood Services (Richmond, VA), or leukapheresis of volunteers, either locally or commercially from BRT Laboratories (Baltimore, MD). These were collected under IRB approved protocols (HIC 10598, 12382). T-cell subsets were isolated from PBMC by the Miltenyi Biotech MACS system according to the manufacturer's instructions (Auburn, CA, Catalog # 130-091-154 for CD8 + T cells; Catalog #130-091-155 and 130-090-445 for  CD4   +   CD25  ¡ T cells, and Catalog #130-091-301 for  CD4   +   CD25 high T cells). The resulting T cell subpopulations were assessed for purity by Xow cytometry and were only used if ¸90% pure. All of the cells were cultured in RPMI 1640 medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (Gemini Bio-Products, Woodland, CA), 2 mM L-glutamine, penicillin (100 units/ml), and streptomycin (100 g/ml) at 37°C in 5% CO 2 
Reagents and inhibitors
Sorafenib (BAY43-9006) was purchased from Calbiochem (Catalog #553011). Sirolimus (Rapamycin) was purchased from LC Laboratories (Woburn, MA; R-5000). Stock solutions were made of each agent in DMSO. For all assays, the negative control was a solution containing DMSO at the same concentration ("vehicle"). IL-2 was purchased from Chiron (Emeryville, CA; Proleukin) and used at 1,000 IU/ml.
Cell proliferation assays
For experiments to examine the eVects of the signal transduction inhibitors on lymphocyte cell proliferation, lymphocytes were plated (30,000 cells per well) in triplicate in Xat-bottom 96-well plates (Costar 3610); in RPMI1640 (Sigma), medium supplemented with 10% FBS, glutamine, and pen-strep; they were treated with inhibitor or vehicle at the indicated concentrations then, after an hour, were either stimulated or not with CD3/CD28 Dynabeads (Invitrogen Catalog #111-31D; 2.5 l beads/10 6 T cells; 4 £ 10 7 beads/ ml in PBS pH 7.4 with 0.1% human serum albumin). Exogenous cytokines were not used. Lymphocytes were cultured 72 h, and then cell numbers were assayed by measure of intracellular ATP using Cell Titer Glo (Promega Catalog#G7571; Madison, WI), according to manufacturer instructions. Mean values were calculated and plotted, with error bars representing the standard deviation of triplicate samples from at least three independent experiments. Triplicate values were all within 8.5%. For time-course studies, all lymphocytes were plated and treated at the same time, and plates were read by the luminometer at the time points indicated (6, 12, 24, 36 , 48 h later, etc.). The time-course experiments were done twice, with triplicate wells for each time point, for each experiment.
Apoptosis assays
T cells were treated with vehicle, 10 nM Sirolimus or 10 nM Sorafenib and after an hour stimulated with CD3/ CD28 beads and incubated for 12 or 24 h as indicated. Cells were then surface stained for CD4 (CD4-FITC), CD25 (CD25-PE), and CD8 (CD8-APC-Cy7) as described above. After surface staining cells, they were washed once in FACS buVer [0.1% BSA and 0.1% NaN3 (azide) in PBS], once in PBS, and then once more in freshly prepared binding buVer, (10£ solution from BDbiosciences Catalog #51-66121E). Annexin V-APC (BDbiosciences Catalog #550474) was added at a Wnal dilution of 1:10 or 1:20 from the original stock in 1£ binding buVer containing 7AAD (1 g/ml; CalBiochem Catalog #129935). The dilution of Annexin V-APC used was based on the number of cells. Cells were pelleted, the buVer was decanted, and cells were gently suspended in residual buVer to which was added 0.02 ml of Annexin V-APC and 7AAD. Appropriate compensation controls and FMOs were performed in conjunction.
Human subjects
All the research involving human subjects was approved by the University of Virginia's IRB (Human Investigation Committee) in accordance with assurances Wled with and approved by the Department of Health and Human Services.
Results
EVect of Sirolimus or Sorafenib on CD4
+ CD25 high T cells
We separated peripheral blood mononuclear cells (PBMCs) from healthy donors and isolated CD4 + CD25 high T cells as described previously using the Miltenyi MACS system [5, 6, 8, 9, 11, 18-20, 28, 29] . Cells were analyzed by Xow cytometry and found to be ¸90% CD4 + CD25 high (Fig. 1a) . PuriWed CD4 + CD25 high T cells did not proliferate without stimulation, but when stimulated with CD3/CD28, the number of cells increased up to 3-fold after 72 h (responses were variable among diVerent donors). Treatment with Sirolimus or Sorafenib for 1 h prior to stimulation by CD3/ CD28 caused a dose-dependent reduction in the number of these T cells, where the eVects were similar for the two agents (Fig. 1b) . The dose-response curve revealed inhibition of proliferation below 3 nM Sirolimus or Sorafenib. At 3 nM, there was essentially no proliferation (Fig. 1b , dashed line) and at higher concentrations of 10 nM (Fig. 1b) and 100 nM (data not shown), there was a near complete net loss in the number of viable CD4 + CD25 high T cells. Thus, some doses of Sirolimus and Sorafenib below 10 nM were cytotoxic for CD3/CD28-stimulated CD4 + CD25 high T cells. The time dependence of the cytotoxic response was examined (Fig. 1c) (Fig. 2b) . These T-cell subsets were pre-treated with Sirolimus or Sorafenib, then stimulated with CD3/CD28 to engage the T-cell receptor. CD4 + T cells increased in number by 150-200% after T-cell receptor engagement, as shown in Fig. 2c , open bar. Pre-treatment with either Sirolimus (hatched bars) or Sorafenib (solid bars) at 0.01 to 100 nM caused a dose-dependent decrease in proliferation (Fig. 2c) . At these very low doses, a 10 4 -fold change in concentration resulted in only about a 50% decrease in proliferation. We note that therapeutic doses of these agents produce serum levels (100 M Sirolimus [21] , 10 M Sorafenib [10, 24] ) that are 100-1,000 times higher than the concentrations tested here. When CD4 + T cells were treated with Sirolimus plus Sorafenib, in combination, at concentrations ranging from 0.01 to 100 nM, there was a net decrease in cell number relative to the initial input (data not shown). CD8 + T cells were more responsive to CD3/CD28 stimulation, increasing in number nearly 500% (Fig. 2d , open bar). Addition of even the lowest dose (0.01 nM) of Sirolimus (hatched bars) or Sorafenib (solid bars) decreased this response by nearly 50% (Fig. 2d) . A 10 4 increase in dose resulted in little further inhibition. Thus, both CD4 + and CD8 + T cells survived in the presence of these doses of Sirolimus or Sorafenib, and CD8 + T cells continued to proliferate under these conditions. The time dependence of the inhibitory eVect of Sirolimus and Sorafenib on CD4 + and CD8 + T cell proliferation was examined. CD4 + T cells treated with vehicle, as a control, and stimulated with CD3/CD28 began to increase in number after 12 h (Fig. 2e, dashed line) . In the presence of either 10 nM Sirolimus (open circles) or 10 nM Sorafenib (closed squares), the number of CD4 + T cells did not change signiWcantly over 72 h (Fig. 2e) . However, we point out that in the absence of drugs, the number of CD4+T cells increased during this time period (dotted line). By comparison, CD8 + T cells resisted inhibitory eVects of low dose Sirolimus or Sorafenib and increased in cell number parallel to the control starting 4 h after addition of CD3/CD28 beads (Fig. 2f ). These data demonstrate that low nanomolar doses of Sirolimus and Sorafenib were not cytotoxic for either the CD4 + or CD8 + T cell populations, a distinctly diVerent response than with the CD4 + CD25
high T cells (Fig. 1c) (Fig. 3) . Compared to treatment with vehicle (left column), CD4 + T cells treated with either Sirolimus (center column) or Sorafenib (right column) exhibited an average (n = 3) 4-to 5-fold increase in the percentage of apoptotic and non-viable cells (Fig. 3a) . Thus, the lack of change in the number of CD4 + T cells cultured in the presence of Sirolimus or Sorafenib (see Fig. 2e ) likely reXects a balance of cell death and cell proliferation. The proliferation of CD4 + T cells was evident in the absence of Sirolimus or Sorafenib (Fig. 2c) . Treatment of CD8 + T cells with either Sirolimus or Sorafenib caused an average (n = 3) 2-to 3-fold increase in apoptotic and non-viable cells (Fig. 3b) . The low observed incidence of apoptosis in the CD8 + population is consistent with a net increase in cell number in the presence of Sirolimus or Sorafenib (Fig. 2f, see  above) . CD4 + CD25 high T cells treated with either Sirolimus or Sorafenib had an average (n = 2) 4-to 6-fold increase in apoptotic and non-viable cells at 12 h (Fig. 3c) . At 24 h after treatment with Sirolimus or Sorafenib, the percentage of apoptotic and non-viable cells increased further to 36 and 27%, respectively (Fig. 3d) . Thus, Sirolimus and Sorafenib induced apoptosis and cell death in CD4 + CD25 high T cell population. high T cells from healthy donors with Sirolimus or Sorafenib and after an hour, stimulated them (or not) with CD3/CD28. Without stimulation by CD3/CD28 (Fig. 4a) , the number of apoptotic or non-viable CD4 + CD25
high T cells at 24 h was not increased by treatment with either Sirolimus (center column) or Sorafenib (right column) compared to vehicle (left column). CD4 + CD25
high T cells from the same donor stimulated with CD3/CD28 showed a signiWcant increase in the number of apoptotic and non-viable cells after treatment with Sirolimus or Sorafenib (Fig. 4b) . Similar results were obtained with CD4 Fig. 5) . Sirolimus produced dose-dependent inhibition of CD4 + CD25 high T cell proliferation in response to TCR activation (Fig. 5 , columns 3-5), and this response was completely blocked by addition of IL-2 to the cultures (Fig. 5, columns 6-8) . In controls without TCR activation, apoptosis of CD4 + CD25 high T cells was not increased by Sirolimus, with or without IL-2 (not shown). Thus, IL-2 prevented the cytotoxic eVect of Sirolimus on CD3/CD28-stimulated CD4 + CD25 high T cells.
Discussion
We began these in vitro studies because of our interest in using targeted therapies in conjunction with immunotherapy for melanoma treatment. We have found that nanomolar doses of Sirolimus and Sorafenib inhibit human melanoma cell proliferation and that combination of these and other agents are cytotoxic for human melanoma cells [14, 15] . One of our concerns with use of these targeted agents is their potential immunosuppressive eVects, even at 
b CD4
+ CD25 high T cells from the same donor were treated as described in a except 1 h after addition of drugs, cells were stimulated with CD3/ CD28 and analyzed at 24 h. These results were replicated with CD4 + CD25 high T cells isolated from two additional normal donors high T cells when they were treated with Sirolimus or Sorafenib at <10 nM. This apoptotic eVect was completely ablated by the addition of IL-2 to the culture medium. This eVect could be due to activation of proliferation signals or a change in the balance of pro-versus anti-apoptotic signals. We imagine that there is opposing signaling by the T-cell receptor and the IL-2 receptor that determines the apoptotic response to Sirolimus (Fig. 6) .
The mechanism for diVerential susceptibility of T cell subsets to Sirolimus or Sorafenib remains unknown. There was a dramatic loss of CD4 + CD25 high T cells above a 3 nM threshold dose. This titration eVect is consistent with a prior report [23] and suggests titration of a limiting factor essential for CD4 + CD25
high T cell survival that is induced by stimulation with CD3/CD28. Thus, an intriguing question is whether there is there a common target for Sirolimus and Sorafenib. One simple explanation would be a protein inhibited by both drugs. Sirolimus and Sorafenib both inhibit protein kinases. These chemical agents have distinctive structural backbones and act by diVerent mechanisms. Sirolimus is a macrolide that targets a prolyl-isomerase (FKBP12) that, in turn, binds and inhibits mTOR kinase at a site separate from the kinase domain. On the other hand, Sorafenib (aka:BAY43-9006, N-(3-triXuoromethyl-4-chlorophenyl)-NЈ-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea), inhibits Raf and VEGFR kinases by competing with ATP for binding at the active site in the kinase domain. These considerations make it unlikely that Sirolimus and Sorafenib compete for a single intracellular receptor to trigger apoptosis in CD4 + CD25 high T cells. It is possible that there is an unrecognized common target for Sirolimus and Sorafenib, but our results predict that the target must: (1) bind both compounds with nanomolar aYnity, (2) be induced by CD3/CD28 stimulation and (3) be essential for CD4 + CD25 high T cell survival, and not survival of CD4 + or CD8 + T cells. Comparative proteomic analyses of diVerent T cell subsets could be employed to identify new nanomolar aYnity targets for Sirolimus and Sorafenib. Alternatively, inhibition of the recognized targets of Sirolimus and Sorafenib (FKBP12/mTOR and Raf) might, by separate pathways, extinguish an unidentiWed signal that is critical for survival of CD4 + CD25 high T cells. In contrast to the Wndings in the current manuscript, others have reported that Sirolimus selectively expands CD4 + CD25 high T cells in vitro [2, 23] . In that work, naïve murine CD4 + T cells were stimulated with antigen plus IL-2, in the presence or absence of 100 nM Sirolimus and cultured 4 weeks. At the end of that time, there was a relative expansion of the CD4 + CD25 high T cell subset without a signiWcant change in the total cell number. This could be explained either by selective expansion of CD4 + CD25 high cells [2] or by conversion of CD4 + cells to CD4 + CD25 high [25] . These reports may seem to contradict our observations of inhibitory and cytotoxic responses of CD4 + CD25 high T cells to nanomolar concentrations of Sirolimus. However, in those reports, IL-2 was included in long-term cultures of T cells prior to their challenge with Sirolimus [2, 23] . We have found that IL-2 rendered CD4 + CD25 high T cells resistant to cytotoxic eVects of Sirolimus. There are other diVerences between the two studies: it is possible that long-term cultures (weeks) with IL-2 may produce major changes in gene expression that could aVect their response to Sirolimus. In our experiments, Sirolimus and IL-2 were added within an hour of each other, making it less likely that activation of transcription and translation by IL-2 was responsible for the resistance to Sirolimus. We think it more likely that signaling from the activated IL-2 receptor modiWed existing proteins to make CD4 + CD25 high T cells resistant to the inhibition by Sirolimus. We propose that IL-2 may stimulate anti-apoptotic signals that make the CD4 + CD25
high T cells resistant to the pro-apoptotic eVects of Sirolimus (Fig. 6) .
